Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take aim at autoimmune diseases

NCT ID NCT07305116

First seen Jan 05, 2026 · Last updated May 20, 2026 · Updated 24 times

Summary

This early-stage study is testing a new treatment for people with certain autoimmune diseases like lupus and kidney disease. The treatment uses specially engineered immune cells (CAR T-cells) that target and attack faulty immune cells causing the disease. The main goal is to check if the treatment is safe and to find the right dose in 15 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310052, China

Conditions

Explore the condition pages connected to this study.